Sigrid S. Skanland

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.

Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.

Journal: British journal of haematology

Published: February 13, 2026

The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

Journal: Molecular oncology

Published: September 01, 2025

Targeting proteostasis in multiple myeloma through inhibition of LTK.

Targeting proteostasis in multiple myeloma through inhibition of LTK.

Journal: Leukemia

Published: September 08, 2024

Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.

Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 04, 2024

Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient.

Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient.

Journal: Cell death & disease

Published: September 02, 2024

PI3K Inhibitors in Hematology: When One Door Closes….

PI3K Inhibitors in Hematology: When One Door Closes….

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 25, 2024

Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3.

Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3.

Journal: iScience

Published: February 09, 2024

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.

Journal: Science (New York, N.Y.)

Published: February 01, 2024

Immunophenotyping with (phospho)protein profiling and fluorescent cell barcoding for single-cell signaling analysis and biomarker discovery.

Immunophenotyping with (phospho)protein profiling and fluorescent cell barcoding for single-cell signaling analysis and biomarker discovery.

Journal: NPJ precision oncology

Published: November 03, 2023

Standardized assays to monitor drug sensitivity in hematologic cancers.

Standardized assays to monitor drug sensitivity in hematologic cancers.

Journal: Cell death discovery

Published: July 13, 2023

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Journal: Nature communications

Published: June 19, 2023

Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling.

Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling.

Journal: Cell reports methods

Published: March 15, 2023

Showing 1-12 of 42

Last Updated: 09/26/2026